Alternatively, to specifically avoid NK cell attenuation and eliminate NGFRhigh cells—which have additionally been shown to emerge as resistant cells toward common melanoma therapies (56)—genetically engineered CAR-NGFR NK cells with cytotoxicity enhancers could be used in combination with conventional melanoma therapies. Here, NGFR is linked to melanoma.